Wegovy sales double to boost Novo Nordisk's fourth quarter but slower growth predicted
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback